G&E Herbal Biotechnology Co., Ltd.: Pioneering Botanical Drug Discovery and Phytochemical Development
Corporate Overview
G&E Herbal Biotechnology Co., Ltd. (legally registered in Taiwan as 德英生物科技股份有限公司) is a publicly traded, research-driven biotechnology and pharmaceutical manufacturing enterprise. Established on August 6, 2002, and listed on the Taipei Exchange (TPEx) under stock code 4911, the company specializes in translating botanical science into modern, validated medical breakthroughs, therapeutic compounds, and specialized skin and liver-health products.
Headquartered in the Southern Taiwan Science Park in the Annan District of Tainan City, Taiwan, G&E was integrated into the science park as an approved high-tech enterprise under the auspices of the National Science Council. Led by Founder and Chairman Professor Kou-Wha Kuo—who previously spent over two decades dedicating his clinical research to the Institute of Biochemistry at Kaohsiung Medical University—the company manages an interdisciplinary scientific ecosystem spanning molecular biology, pharmacology, physiology, chemistry, horticulture, and quality control. G&E operates a state-of-the-art, validated PIC/S GMP formulation plant completed in 2018 to manufacture its proprietary botanical extractions and therapeutic preparations under international safety baselines.
Continue…
Core Scientific Breakthrough: The SR-100 Platform
The fundamental pillar of G&E's IP portfolio is its patented plant extraction technology known as SR-100. Derived from specialized plant species indigenous to Taiwan, the SR-100 platform isolates precise solasodine rhamnosyl glycosides, which show highly selective, targeted action against damaged or hyper-proliferative cells without destroying adjacent healthy tissue.
The company has expanded this core discovery across a spectrum of oncology, dermatological, and clinical wellness applications. Instead of relying on traditional synthetic chemistry, G&E utilizes advanced phytochemical refinement processes to achieve highly stable, repeatable active pharmaceutical ingredients (APIs). The technological platform has garnered over 296 international patents and trademarks across markets including the United States, Europe, mainland China, Malaysia, Australia, and South Africa.
Primary Products and Therapeutic Offerings
G&E segments its commercial portfolio into clinical pharmaceuticals, over-the-counter liver protectants, specialized functional cosmetics, and botanical topical agents:
1. Advanced Drug Pipeline (Oncology and Dermatology)
- SR-T100 Topical Gel: The company’s flagship investigational botanical drug. SR-T100 has successfully advanced through clinical pipelines in Taiwan and the United States. It underwent Phase III clinical trials in Taiwan for the treatment of cutaneous squamous cell carcinoma in situ (specifically targeting actinic keratosis, a pre-cancerous skin condition). The trial received major validation from the Ministry of Economic Affairs A+ Corporate Innovation Program as a continuing exemplary case.
- SR-T100 Injection: Engineered as a direct injection therapeutic, G&E submitted this compound to the Ministry of Health and Welfare (MOHW) and the Center for Drug Evaluation (CDE) for human clinical trial consultations, broadening its application boundaries beyond topical skin structures.
2. Hepatoprotective Agents (Liver Health)
- HepaGent™ / Hepanamin® (德英 樂必妥脂膠囊): An enterprise-grade, clinically backed liver protective capsule containing 70 mg of standardized active botanical extract. This formulation is indicated for optimizing metabolic liver function, treating chronic liver disease, and mitigating liver fat accumulation. Hepanamin® has completed intensive multi-year long-term stability testing, establishing an accredited 4-year shelf life, and is exported extensively throughout Southeast Asia, including Singapore.
3. SR-100 Functional Cosmetics and Anti-Aging Skincare
Leveraging the anti-inflammatory and cellular renewal profile of the SR-100 complex, G&E manufactures an advanced line of botanical cosmeceuticals aimed at mitigating skin degradation, redness, and micro-inflammation:
* Botanical Cleansing Essence: A non-irritating facial wash engineered to clear impurities while preserving the skin's lipid barrier.
* Botanique Extract Toner: A soothing, liquid-suspension extract designed to balance localized skin pH and prepare tissue for deep hydration.
* Moisturizing Cream & Targeted Serums: High-potency topical layers combining the SR-100 isolate with standard bioactive carrier oils to target skin aging and age-related tissue thinning.
* Essential Oils: Tailored botanical distillates intended for specialized clinical wellness and spa integration.
4. Specialized Topical Ointments and Lubricants
- SR-100 Botanical Topical Ointments: Highly concentrated soothing creams engineered to repair compromised skin barriers, manage chronic irritation, and calm localized inflammatory episodes.
- SR-100 Lubricant / Smile Cream: Specialized mucosal-safe formulations designed to offer physiological comfort, tissue hydration, and protective barriers without interrupting sensitive flora structures.
B2B Services and CDMO Capabilities
Beyond selling proprietary brands, G&E leverages its manufacturing asset footprint in Tainan City to provide contract services to external global partners:
- Contract Development and Manufacturing Organization (CDMO) Services: backed by more than 20 years of active plant-extraction and formulation experience, G&E offers specialized botanical CDMO services. This includes scaling raw agricultural botanicals into verified, standard-compliant liquid, gel, and capsule formats under strict PIC/S GMP conditions.
- Strategic Licensing and International Distribution: The entity actively negotiates global outbound licensing agreements for its oncology and wart-treatment pipelines, maintaining commercial partnerships and memoranda of understanding (MOUs) with international pharmaceutical distributors across Japan, Europe, and Asia-Pacific.
